Janssen Announces U.S. FDA Approval of First and Only Complete, Single-Pill, Two-Drug Regimen, JULUCA ® (Dolutegravir and Rilpivirine), for the Treatment of HIV-1 Infection

Provides New Treatment Option for Stable, Virologically Suppressed Adults Living with HIV-1
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news